Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Fred R HirschLecia V SequistIra GoreMeghan J MooradianGeorge SimonElisabeth F CroftDiana DeVincenzoJiefen MunleyDara SteinKlaus FreivogelFrangiscos SifakisPaul A BunnPublished in: Cancer (2018)
A subset of long-term NSCLC survivors who were receiving gefitinib had an excellent long-term safety profile. Although it is assumed that most of these patients' tumors harbor EGFR mutations, molecular studies of available tumor specimens are planned to uncover the features that predict long-term survival. Cancer 2018;124:2407-14. © 2018 American Cancer Society.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- small cell lung cancer
- papillary thyroid
- tyrosine kinase
- end stage renal disease
- squamous cell
- newly diagnosed
- young adults
- prognostic factors
- squamous cell carcinoma
- brain metastases
- quality improvement
- lymph node metastasis
- case control
- free survival